Immutep (XTER:YP1A) Change In Receivables : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Immutep Change In Receivables?

Immutep's change in receivables for the quarter that ended in Dec. 2023 was €0.00 Mil. It means Immutep's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Immutep's change in receivables for the fiscal year that ended in Jun. 2023 was €0.00 Mil. It means Immutep's Accounts Receivable stayed the same from Jun. 2022 to Jun. 2023 .

Immutep's Accounts Receivable for the quarter that ended in Dec. 2023 was €0.10 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Immutep's liquidation value for the three months ended in Dec. 2023 was €58.75 Mil.

Immutep Change In Receivables Historical Data

The historical data trend for Immutep's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Change In Receivables Chart

Immutep Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Receivables

Get a 7-Day Free Trial

Immutep Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Immutep Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Immutep (XTER:YP1A) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Immutep's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.099	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Immutep's accounts receivable are only considered to be worth 75% of book value:

Immutep's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	63.671	-	5	+	0.75 * 0.099	+	0.5 * 0
=	58.75

Immutep Change In Receivables Related Terms

Thank you for viewing the detailed overview of Immutep's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Immutep (XTER:YP1A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (XTER:YP1A) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

PRRUF:USA IMMP:USA YP1B:Germany IMM:Australia

Address

264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000

Website

https://www.immutep.com

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Immutep (XTER:YP1A) Headlines

No Headlines